Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Alpine Immune Sciences Inc | ALPN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 64.97 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 64.97 | 64.97 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 8.33 - 65.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 64.97 | USD |
Alpine Immune Sciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 4.46B | - | - | - | -264.27 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alpine Immune Sciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALPN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 64.98 | 65.00 | 64.97 | 64.97 | 4,285,633 | -0.01 | -0.02% |
| 3 Months | 41.32 | 65.00 | 34.25 | 59.44 | 2,983,408 | 23.65 | 57.24% |
| 6 Months | 18.96 | 65.00 | 17.32 | 47.53 | 1,819,256 | 46.01 | 242.67% |
| 1 Year | 11.21 | 65.00 | 8.33 | 39.56 | 1,079,374 | 53.76 | 479.57% |
| 3 Years | 8.85 | 65.00 | 4.82 | 34.17 | 413,832 | 56.12 | 634.12% |
| 5 Years | 4.38 | 65.00 | 2.05 | 29.43 | 307,023 | 60.59 | 1,383.33% |
Alpine Immune Sciences Description
| Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202. |
